Smith & Nephew SNATS ROA 2006-2018 | SNN

Current and historical return on assets (ROA) values for Smith & Nephew SNATS (SNN) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Smith & Nephew SNATS ROA for the three months ending June 30, 2018 was 0.00%.
Smith & Nephew SNATS ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2018-06-30 $0.00B $7.71B 0.00%
2017-12-31 $0.00B $7.87B 0.00%
2017-06-30 $0.00B $7.44B 0.00%
2016-12-31 $0.16B $7.34B 2.20%
2015-12-31 $0.26B $7.17B 3.57%
2015-06-30 $0.35B $7.22B 4.69%
2014-12-31 $0.50B $7.31B 7.00%
2014-09-30 $0.50B $7.65B 7.41%
2014-06-30 $0.52B $7.74B 8.35%
2014-03-31 $0.56B $5.94B 9.89%
2013-12-31 $0.56B $5.82B 9.97%
2013-09-30 $0.54B $5.57B 9.69%
2013-06-30 $0.55B $5.45B 10.17%
2013-03-31 $0.71B $5.47B 13.60%
2012-12-31 $0.73B $5.64B 14.34%
2012-09-30 $0.73B $5.00B 14.96%
2012-06-30 $0.73B $4.81B 15.07%
2012-03-31 $0.59B $4.88B 12.13%
2011-12-31 $0.58B $4.75B 12.08%
2011-09-30 $0.62B $4.82B 12.96%
2011-06-30 $0.63B $4.91B 13.01%
2011-03-31 $0.61B $4.79B 12.90%
2010-12-31 $0.62B $4.73B 13.13%
2010-09-30 $0.56B $4.88B 12.09%
2010-06-30 $0.55B $4.58B 12.06%
2010-03-31 $0.53B $4.54B 11.69%
2009-12-31 $0.47B $4.57B 10.48%
2009-09-30 $0.46B $4.63B 10.22%
2009-06-30 $0.41B $4.52B 9.07%
2009-03-31 $0.39B $4.31B 8.64%
2008-12-31 $0.38B $4.51B 8.15%
2008-09-30 $0.36B $4.53B 7.87%
2008-06-30 $0.30B $4.71B 6.63%
2008-03-31 $0.31B $4.67B 6.99%
2007-12-31 $0.32B $4.45B 7.81%
2007-09-30 $0.36B $4.28B 9.49%
2007-06-30 $0.44B $4.23B 12.53%
2007-03-31 $0.42B $3.22B 13.24%
2006-12-31 $0.75B $3.23B 23.69%
2006-09-30 $0.70B $3.20B 22.12%
2006-06-30 $0.67B $3.16B 21.52%
2006-03-31 $0.67B $3.10B 21.59%
2005-12-31 $0.34B $3.19B 11.10%
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $16.143B $4.765B
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $127.843B 25.90
Medtronic (MDT) Ireland $127.434B 19.54
Stryker (SYK) United States $64.080B 24.15
Boston Scientific (BSX) United States $53.415B 26.99
Baxter (BAX) United States $33.780B 21.81
Zimmer Biomet Holdings (ZBH) United States $23.992B 15.56
ResMed (RMD) United States $15.239B 29.06
Canopy Growth (CGC) Canada $9.087B 0.00
Perrigo (PRGO) Ireland $8.704B 13.21
Bio-Rad Laboratories (BIO) United States $8.282B 52.95
Aurora Cannabis (ACB) Canada $7.005B 66.27
Hill-Rom Holdings (HRC) United States $6.451B 20.45
Haemonetics (HAE) United States $5.768B 50.73
Insulet (PODD) United States $5.175B 0.00
ICU Medical (ICUI) United States $4.749B 26.49
Hutchison China MediTech (HCM) China $4.266B 0.00
GW Pharmaceuticals (GWPH) United Kingdom $4.158B 0.00
Agios Pharmaceuticals (AGIO) United States $4.020B 0.00
Neogen (NEOG) United States $3.320B 50.28
National Vision Holdings (EYE) United States $3.309B 73.08
Aphria (APHA) $3.074B 0.00
NuVasive (NUVA) United States $2.979B 27.72
Quidel (QDEL) United States $2.599B 33.88
NxStage Medical (NXTM) United States $1.933B 0.00
Phibro Animal Health (PAHC) United States $1.498B 21.20
AtriCure (ATRC) United States $1.262B 0.00
Cardiovascular Systems (CSII) United States $1.079B 1554.50
VAREX IMAGING (VREX) United States $1.035B 16.91
PetIQ (PETQ) United States $0.874B 28.60
Surmodics (SRDX) United States $0.855B 130.61
Meridian Bioscience (VIVO) United States $0.836B 26.65
OraSure Technologies (OSUR) United States $0.797B 44.86
Cerus (CERS) United States $0.778B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.775B 24.86
MacroGenics (MGNX) United States $0.734B 0.00
Omeros (OMER) United States $0.638B 0.00
Lantheus Holdings (LNTH) United States $0.575B 17.81
Insys Therapeutics (INSY) United States $0.568B 0.00
Owens & Minor (OMI) United States $0.567B 6.41
LeMaitre Vascular (LMAT) United States $0.527B 25.89
NanoString Technologies (NSTG) United States $0.475B 0.00
TG Therapeutics (TGTX) United States $0.459B 0.00
Evolus (EOLS) United States $0.416B 0.00
Quanterix (QTRX) United States $0.372B 0.00
Utah Medical Products (UTMD) United States $0.327B 21.12
Cytosorbents (CTSO) United States $0.312B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.280B 0.00
BioLife Solutions (BLFS) United States $0.258B 348.50
Surface Oncology (SURF) United States $0.227B 0.00
Rockwell Medical (RMTI) United States $0.225B 0.00
Chimerix (CMRX) United States $0.168B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.162B 0.00
Fonar (FONR) United States $0.143B 7.20
Chembio Diagnostics (CEMI) United States $0.117B 0.00
Imprimis Pharmaceuticals (IMMY) United States $0.091B 0.00
United-Guardian (UG) United States $0.080B 16.85
Female Health (VERU) United States $0.077B 0.00
Oramed Pharmaceuticals (ORMP) Israel $0.074B 0.00
Trinity Biotech (TRIB) Ireland $0.068B 21.60
Neurotrope (NTRP) United States $0.055B 0.00
CAS Medical Systems (CASM) United States $0.054B 0.00
ImmuCell (ICCC) United States $0.042B 0.00
Capricor Therapeutics (CAPR) United States $0.030B 0.00
Valeritas Holdings (VLRX) United States $0.027B 0.00
Senestech (SNES) United States $0.020B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.015B 0.00
Cellectar Biosciences (CLRB) United States $0.009B 0.00
NeuroMetrix (NURO) United States $0.007B 0.00
Akers Biosciences Inc (AKER) United States $0.000B 0.00